Update on Human Papillomavirus Vaccines: Life Saver or Controversy Magnet?

Clinical Microbiology Newsletter

Volumn 34, Issue 11, 2012, Pages 85-91

  Bergman, Scott J ^a   Collins Lucey, Emily ^b  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^b ST JOHN S MERCY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION PREVENTION; INFECTION RESISTANCE; INJECTION SITE PAIN; PAPILLOMAVIRUS INFECTION; SEX DIFFERENCE; SYNCOPE; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; VENOUS THROMBOEMBOLISM;

EID: 84861210106     PISSN: 01964399     EISSN: 18734391     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2012.05.001     Document Type: Article

References (51)

1. World Health Organization Viral cancers, human papillomavirus (Accessed on 29 Jan. 2011. http://www.who.int/vaccine_research/diseases/viral_cancers/en/index3.html.
2. Munoz N., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348:518-527.
3. Merck & Co, Inc. Gardasil Prescribing information (Accessed 29 Jan. 2011.). http://www.merckvaccines.com/Products/Gardasil/Pages/home.aspx.
4. National Cancer Institute Cervical cancer (Accessed 14 Dec. 2010.). http://www.cancer.gov/cancertopics/types/cervical.
5. Walboomers J.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
6. Kim J.J. Weighing the benefits and costs of HPV vaccination of young men. N. Engl. J. Med. 2011, 364:393-395.
7. Eaton D.K., et al. Youth risk behavior surveillance - United States, 2009. MMWR Surveill. Summ. 2010, 59:1-142.
8. Munoz N., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
9. GlaxoSmithKline Cervarix prescribing information (Accessed 29 Jan. 2011.). http://www.cervarix.com.
10. Zimmerman R.K., et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J. Womens Health 2010, 19:1441-1447.
11. Anonymous. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 59: 626-629.
12. Centers for Disease Control and Prevention Adult vaccination coverage, the National Health Interview Survey (NHIS). Center for Disease Control and Prevention (Accessed 8 Jan. 2011.). http://cdc.gov/vaccines/stats-surv/nhis/2009-nhis.htm.
13. Pagliusi S.R., Aguado M.Teresa Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004, 23:569-578.
14. Villa L.L., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005, 6:271-278.
15. Villa L.L., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 2006, 95:1459-1466.
16. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 2007, 356:1915-1927.
17. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861-1868.
18. Joura E.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369:1693-1702.
19. Garland S.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007, 356:1928-1943.
20. Dillner J., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. Br. Med. J. 2010, 341:c3493.
21. Yancey A.M., Pitlick J.M., Forinash A.B. The prophylactic role for the human papillomavirus quadrivalent vaccine in males. Ann. Pharmacother. 2010, 44:1314-1318.
22. Block S.L., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118:2135-2145.
23. Reisinger K.S., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr. Infect. Dis. J. 2007, 26:201-209.
24. Vesikari T., et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr. Infect. Dis. J. 2010, 29:314-318.
25. Reisinger K.S., et al. Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010, 125:1142-1151.
26. Wilkin T., et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J. Infect. Dis. 2010, 202:1246-1253.
27. Giuliano A.R., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 2011, 364:401-411.
28. Pelefsky, J. and A. Guilano. 2009. Quadrivalent HPV vaccine efficacy in men having sex with men. Presented at the 25th International Papillomavirus Conference. Malmo, Sweden.
29. Pelesfsky, J. 2010. Efficacy of the quadrivalent HPV vaccine to prevent anal intraepitherlial neoplasia among young men who have sex with men. 26th International Papillomavirus Conference. Montreal, Canada.
30. Romanowski B., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
31. Paavonen J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
32. Brown D.R., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 2009, 199:926-935.
33. Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 2009, 199:936-944.
34. Munoz N., et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl. Cancer Inst. 2010, 102:325-339.
35. Einstein M.H., et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 2009, 5:705-719.
36. Syncope after vaccination-United States, January 2005-July 2007. MMWR Morb. Mortal. Wkly. Rep. 2008, 57:457-460.
37. Slade B.A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302:750-757.
38. Wacholder S., et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. Br. Med. J. 2010, 340:c712.
39. Forinash A.B., et al. Safety of the HPV bivalent and quadrivalent vaccines during pregnancy. Ann. Pharmacother. 2011, 45:258-262.
40. Olsson S.E., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007, 25:4931-4939.
41. Herrero R., et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008, 26:4795-4808.
42. Levin M.J., et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J. Acquir. Immune Defic. Syndr. 2010, 55:197-204.
43. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 2008, 359:821-832.
44. GlaxoSmithKline Cervarix is approved in Australia for females 10-45 years old (Accessed 29 Jan. 2011.). http://www.gsk.com/media/pressreleases/2007/2007_05_21_GSK1037.htm.
45. Rothman S.M., Rothman D.J. Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA 2009, 302:781-786.
46. Centers for Disease Control and Prevention Vaccine price list (Accessed 29 Jan. 2011.). http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm.
47. Pomfret T.C., Gagnon J.M., Gilchrist A.T. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J. Clin. Pharm. Ther. 2011, 36:1-9.
48. Manuri P.R., et al. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007, 25:3302-3310.
49. Paavonen J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
50. Kjaer S.K., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. 2009, 2:868-878.
51. Food and Drug Administration Product approval-prescribing information (package insert). Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and18] vaccine, recombinant), Merck & Co., Inc. (Accessed May 25, 2010.). http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm094042.htm.